Moderna Cancer Vaccine Cuts Melanoma Risk While Shares Fall
A personalized mRNA vaccine combined with Merck’s Keytruda cut the risk of melanoma recurrence or death by 42% over two years in a late-stage clinical trial.
Merck
A personalized mRNA vaccine combined with Merck’s Keytruda cut the risk of melanoma recurrence or death by 42% over two years in a late-stage clinical trial.